Peter Greenleaf, Aurinia CEO
Aurinia shareholder calls for sale talks, nixes support for CEO and chair
A 4.2% shareholder of Aurinia Pharmaceuticals is calling on the drugmaker to find a buyer and shake up its board to rid it of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.